Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Vanguard Total Stock Mkt Idx Inv

Vanguard Institutional 500 Index Trust

Capital Group Wash Mutual Invtrs Comp

The Health Care Select Sector SPDR® ETF

JPMorgan Large Cap Growth I

Fidelity Contrafund

Vanguard Institutional Index I

Vanguard Health Care Inv

State St S&P 500® Indx SL Cl III

American Funds American Balanced A

Blackrock Eq Idx Fund CF

iShares Russell 1000 Growth ETF

Vanguard PRIMECAP Inv

SPDR® S&P 500® ETF Trust

Fidelity 500 Index

iShares Core S&P 500 ETF

Vanguard Growth Index Investor

Capital Group Growth Fnd of Amer Comp

American Funds Growth Fund of Amer A

American Funds Washington Mutual A

Lilly Endowment Inc

Vanguard Group Inc

Geode Capital Management, LLC

Morgan Stanley - Brokerage Accounts

State Farm Mutual Automobile Ins Co

International Assets Investment Management, LLC

NORGES BANK

Wellington Management Company LLP

Bank of America Corp

Capital Research Global Investors

Northern Trust Corp

Capital Research & Mgmt Co - Division 3

BlackRock Inc

PNC Financial Services Group Inc

State Street Corp

FMR Inc

T. Rowe Price Associates, Inc.

Capital World Investors

JPMorgan Chase & Co

PRIMECAP Management Company

Eli Lilly and Company

Mr. David A. Ricks

Chairman, CEO & President

Dr. Daniel M. Skovronsky M.D., Ph.D.

EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology

LLY's next earnings is on February 4, 2025 (Before Market Open)

LLY's latest dividend is 1.3 USD on August 15, 2024

Eli Lilly and Company (LLY) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

Eli Lilly and Company (LLY) Earnings Report Date and History | NYSE

LLY's next earnings is on February 4, 2025 (Before Market Open)

When is the earnings report for LLY?

LLY Earnings History

LLY's latest dividend is 1.3 USD on August 15, 2024

LLY Stock Discussion Forum and Message Board

News for NYSE: LLY